# Exploring Endocannabinoid System and Adolescent Psychiatric Risk > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/endocannabinoid-system-adolescent-psychiatric-risk/ > **Published:** 2026-04-14T19:46:06-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:56:10-04:00 > **Clinical Summary:** Explore endocannabinoid system adolescent psychiatric risk linked to cannabis use and mental health disorders in teens with clinical evidence and research insights. --- #### Clinical Takeaway [Adolescent cannabis use](https://cedclinic.com/adolescent-cannabis-use-and-anxiety-research/) is associated with significantly increased risk of developing psychotic, bipolar, depressive, and [anxiety disorders](https://cedclinic.com/cannabidiol-anxiety-treatment-benefits/) in adolescence and young adulthood, based on large-scale longitudinal population data. These findings reflect clinically diagnosed psychiatric conditions, not just symptoms, making the evidence particularly meaningful for clinical practice. Parents, pediatricians, and adolescent patients should understand that cannabis is not low-risk during developmental years. ### #26 Adolescent Cannabis Use and Risk of Psychotic, Bipolar, Depressive, and Anxiety Disorders. **Citation:** Young-Wolff Kelly C et al. *Adolescent [Cannabis Use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) and Risk of Psychotic, Bipolar, Depressive, and Anxiety Disorders.* JAMA health forum. 2026. PMID: 41719031. **Study type:** Journal Article  |  **Topic area:** Psychosis  |  **CED Score:** 10 Design: 0 Journal: 4 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0 **Methodological Considerations:** - Self-reported outcomes — recall and social-desirability bias risk **Abstract:** IMPORTANCE: As cannabis becomes more accessible and socially accepted, concerns have grown about its potential implications for [adolescent mental health](https://cedclinic.com/conduct-disorder-substance-use-disorders-teens/). While prior research has linked adolescent cannabis use to psychiatric symptoms, few large, population-based, longitudinal studies have examined associations with clinically diagnosed psychiatric disorders. OBJECTIVE: To evaluate whether adolescent cannabis use is associated with an increased risk of incident psychotic, bipolar, depressive, and anxiety disorders during adolescence and young adulthood. DESIGN, SETTING, AND PARTICIPANTS: This cohort study included adolescents aged 13 to 17 years who were screened for past-year cannabis use at Kaiser Permanente Northern California from 2016 to 2023. Adolescents were followed up through age 25 years or until December 31, 2023. Data were analyzed from February 21, 2024, to August 27, 2025. EXPOSURE: Time-varying self-reported past-year cannabis use based on universal, confidential screening during standard pediatric care. MAIN OUTCOMES AND MEASURES: Incident clinician-diagnosed psychotic, bipolar, depressive, and anxiety disorders, which were identified through electronic health records using International Classification of Disease codes. Cox proportional hazards regression models were used to measure the strength of associations between adolescent cannabis use and incident psychiatric diagnoses, with adjustments for sex, race and ethnicity, neighborhood deprivation index, insurance type, and time-varying alcohol and other substance use. RESULTS: Of 463 396 adolescents (234 114 males [50.5%]; mean [SD] age, 14.5 [1.3] years) included in the sample, 136 708 were Hispanic individuals (29.5%), 93 737 were non-Hispanic Asian individuals (20.2%), 35 346 were non-Hispanic Black individuals (7.6%), 153 102 were non-Hispanic White individuals (33.0%), and 18 795 individuals were multiracial or of other races or ethnicities (4.1%). At baseline, 26 345 adolescents (5.7%) self-rep  |   |  [View on PubMed ↗](https://pubmed.ncbi.nlm.nih.gov/41719031/)[Full Text ↗](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12924094/)[DOI ↗](https://doi.org/10.1001/jamahealthforum.2025.6839) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Endocannabinoid System and Adolescent Psychiatric Risk](https://cedclinic.com/adolescent-cannabis-use-new-psychiatric-diagnoses-risk/) Detailed exploration of how the [endocannabinoid system](https://cedclinic.com/endocannabinoid-system-fear-extinction/) influences psychiatric risks in adolescents, with clinical insights. [Read More](https://cedclinic.com/adolescent-cannabis-use-new-psychiatric-diagnoses-risk/) [Adolescent Cannabis Use: Psychotic Disorder Risk Guide](https://cedclinic.com/adolescent-cannabis-use-disorder-treatment-guide/) A comprehensive guide on the risk of psychotic disorders linked to adolescent cannabis use, based on clinical data. [Learn More](https://cedclinic.com/adolescent-cannabis-use-disorder-treatment-guide/) [Adolescent Cannabis Use & Mental Health Risk: Clinical Evidence](https://cedclinic.com/adolescent-cannabis-psychotic-disorder-risk/) Clinical evidence highlighting the mental health risks associated with adolescent cannabis use, focusing on psychiatric outcomes. [Explore Study](https://cedclinic.com/adolescent-cannabis-psychotic-disorder-risk/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Exploring%20Endocannabinoid%20System%20and%20Adolescent%20Psychiatric%20Risk&url=https%3A%2F%2Fcedclinic.com%2Fendocannabinoid-system-adolescent-psychiatric-risk%2F) [in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2Fendocannabinoid-system-adolescent-psychiatric-risk%2F) [Share on BlueSky](https://bsky.app/intent/compose?text=Exploring%20Endocannabinoid%20System%20and%20Adolescent%20Psychiatric%20Risk%20https%3A%2F%2Fcedclinic.com%2Fendocannabinoid-system-adolescent-psychiatric-risk%2F) [Follow on Instagram](https://www.instagram.com/drbenjamincaplan) [Read more on Substack](https://doctorapprovedcannabis.substack.com/) [Subscribe via RSS](https://cedclinic.com/feed/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).